» Articles » PMID: 659580

Renin-angiotensin System Inhibition in Conscious Sodium-depleted Dogs. Effects on Systemic and Coronary Hemodynamics

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1978 Apr 1
PMID 659580
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The role of the renin-angiotensin system in the regulation of the systemic and coronary circulations during sodium depletion was studied in conscious normotensive dogs by i.v. administration of teprotide (0.5 mg/kg), an angiotensin-converting enzyme inhibitor, and saralasin (0.05-5 mug/kg per min), an angiotensin-receptor antagonist. Sodium depletion was produced by administering a low sodium diet and furosemide for 5 days. Administration of both teprotide and saralasin lowered systemic arterial blood pressure and total peripheral vascular resistance. Simultaneously, cardiac output increased, but left ventricular end-diastolic pressure, dP/dt, and dP/dt/P did not change significantly. Furthermore, both agents reduced diastolic coronary vascular resistance and increased coronary blood flow, but did not affect myocardial oxygen consumption, left ventricular work, or myocardial efficiency. These systemic and coronary vasodilator effects of teprotide and saralasin, however, were not observed in normal dogs on a regular sodium diet; in this group, the only effect noted was a slight increase in arterial pressure during saralasin infusion. Arterial plasma concentration of norepinephrine did not differ between normal and sodiumdepleted dogs, nor did it change significantly after teprotide administration. These results suggest that, during salt depletion, angiotensin II exerts an active vasoconstrictor action on the systemic and coronary vessels, but has no significant effects on myocardial contractility or energetics. It also appears likely that the increase in cardiac output observed in sodiumdepleted dogs after angiotensin inhibition was caused, at least in part, by the decrease in systemic arterial pressure.

Citing Articles

COVID-19 and Cardiac Arrhythmias: Lesson Learned and Dilemmas.

Blasi F, Vicenzi M, De Ponti R J Clin Med. 2024; 13(23).

PMID: 39685718 PMC: 11642268. DOI: 10.3390/jcm13237259.


Regulation of Coronary Blood Flow.

Goodwill A, Dick G, Kiel A, Tune J Compr Physiol. 2017; 7(2):321-382.

PMID: 28333376 PMC: 5966026. DOI: 10.1002/cphy.c160016.


The renin-angiotensin-aldosterone system and cardiac ischaemia.

Ikram H Heart. 1996; 76(3 Suppl 3):60-7.

PMID: 8983666 PMC: 484490. DOI: 10.1136/hrt.76.3_suppl_3.60.


Angiotensin converting enzyme inhibition in chronic stable angina: effects on myocardial ischaemia and comparison with nifedipine.

Ikram H, Low C, Shirlaw T, Foy S, Crozier I, Richards A Br Heart J. 1994; 71(1):30-3.

PMID: 8297690 PMC: 483605. DOI: 10.1136/hrt.71.1.30.


Left ventricular function and prognosis after myocardial infarction: rationale for therapeutic strategies.

Scognamiglio R, Fasoli G, Nistri S, Marin M, DALLA VOLTA S Cardiovasc Drugs Ther. 1994; 8 Suppl 2:319-25.

PMID: 7947374 DOI: 10.1007/BF00877316.


References
1.
Peart W . THE RENIN-ANGIOTENSIN SYSTEM. Pharmacol Rev. 1965; 17:143-82. View

2.
Johnson J, Davis J . Effects of a specific competitive antagonist of angiotensin II on arterial pressure and adrenal steroid secretion in dogs. Circ Res. 1973; 32:Suppl 1:159-68. View

3.
Wilcken D, CHARLIER A, Hoffman J, Guz A . EFFECTS OF ALTERATIONS IN AORTIC IMPEDANCE ON THE PERFORMANCE OF THE VENTRICLES. Circ Res. 1964; 14:283-93. DOI: 10.1161/01.res.14.4.283. View

4.
RAMSEY L . Analysis of gas in biological fluids by gas chromatography. Science. 1959; 129(3353):900-1. DOI: 10.1126/science.129.3353.900. View

5.
Ferguson R, Turini G, Brunner H, Gavras H, MCKINSTRY D . A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet. 1977; 1(8015):775-8. DOI: 10.1016/s0140-6736(77)92958-0. View